MMAF-OMe is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. In this application, it serves as the cytotoxic payload, designed to kill cancer cells once delivered specifically to the tumor site. The compound is attached to a monoclonal antibody that recognizes and binds to antigens on the surface of cancer cells. Upon internalization, MMAF-OMe is released and exerts its potent anti-mitotic effect by inhibiting microtubule polymerization, leading to cell cycle arrest and apoptosis. This targeted approach minimizes damage to healthy tissues, enhancing the therapeutic window and reducing side effects compared to traditional chemotherapy. Its use is particularly significant in treating hematological malignancies and solid tumors where precise delivery of cytotoxic agents is critical.